Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: Insights from rales (randomized aldactone evaluation study)

Journal of the American College of Cardiology

Volumn 60, Issue 20, 2012, Pages 2082-2089

  Vardeny, Orly ^a   Wu, Dong Hong ^b   Desai, Akshay ^b   Rossignol, Patrick ^c   Zannad, Faiez ^c   Pitt, Bertram ^d   Solomon, Scott D ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

heart failure; renal dysfunction; spironolactone

Indexed keywords

PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; DRUG DOSE TITRATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; WORSENING RENAL FUNCTION;

DIURETICS; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; PROGNOSIS; RISK FACTORS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84868574835     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.07.048     Document Type: Article

References (27)

1. B. Pitt, C.T. Stier Jr., S. Rajagopalan Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease J Renin Angiotensin Aldosterone Syst 4 2003 164 168
2. B. Pitt, F. Zannad, W.J. Remme Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
3. B. Pitt, W. Remme, F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
4. S.A. Hunt, W.T. Abraham, M.H. Chin 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 e1 e90
5. J. Lindenfeld, N.M. Albert, J.P. Boehmer HFSA 2010 Comprehensive Heart Failure Practice Guideline J Card Fail 16 2010 e1 e194
6. F. Zannad, J.J. McMurray, H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
7. P.A. McCullough, A. Ahmad Cardiorenal syndromes World J Cardiol 3 2011 1 9
8. M. Tonelli, C. Bohm, S. Pandeya, J. Gill, A. Levin, B.A. Kiberd Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency Am J Kidney Dis 37 2001 484 489
9. P.A. McCullough, K.R. Sandberg, S. Borzak, M.P. Hudson, M. Garg, H.J. Manley Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease Am Heart J 144 2002 226 232
10. R. Blankstein, G.L. Bakris Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade Heart Fail Clin 4 2008 425 438
11. P. Jose, H. Skali, N. Anavekar Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction J Am Soc Nephrol 17 2006 2886 2891
12. J.M. Testani, S.E. Kimmel, D.L. Dries, S.G. Coca Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction Circ Heart Fail 4 2011 685 691
13. P. Rossignol, J.G. Cleland, S. Bhandari Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Circulation 125 2012 271 279
14. R. Bellomo, C. Ronco, J.A. Kellum, R.L. Mehta, P. Palevsky Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group Crit Care 8 2004 R204 R212
15. M.P. Tokmakova, H. Skali, S. Kenchaiah Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study Circulation 110 2004 3667 3673
16. N.C. Edwards, R.P. Steeds, P.M. Stewart, C.J. Ferro, J.N. Townend Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial J Am Coll Cardiol 54 2009 505 512
17. N.C. Edwards, C.J. Ferro, H. Kirkwood Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease The Am J Cardiol 106 2010 1505 1511
18. S. Shibata, M. Nagase, S. Yoshida Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease Nat Med 14 2008 1370 1376
19. A. Di Zhang, A. Nguyen Dinh Cat, C. Soukaseum Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling Hypertension 52 2008 1060 1067
20. M. Nagase, T. Fujita Aldosterone and glomerular podocyte injury Clin Exp Nephrol 12 2008 233 242
21. H. Kiyomoto, K. Rafiq, M. Mostofa, A. Nishiyama Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury J Pharmacol Sci 108 2008 399 405
22. G.P. Rossi, G. Bernini, G. Desideri Renal damage in primary aldosteronism: results of the PAPY Study Hypertension 48 2006 232 238
23. L.A. Sechi, M. Novello, R. Lapenna Long-term renal outcomes in patients with primary aldosteronism JAMA 295 2006 2638 2645
24. A.S. Bomback, A.V. Kshirsagar, M.A. Amamoo, P.J. Klemmer Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review Am J Kidney Dis 51 2008 199 211
25. S.D. Navaneethan, S.U. Nigwekar, A.R. Sehgal, G.F. Strippoli Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 4 2009 542 551
26. S. Bianchi, R. Bigazzi, V.M. Campese Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease Kidney Int 70 2006 2116 2123
27. D.N. Juurlink, M.M. Mamdani, D.S. Lee Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543 551